Drug Trial Radar · NCT07623642
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
227
Planned (sponsor's estimate)
Start
Jun 2, 2026
Primary completion
Jun 15, 2028
Study completion Aug 15, 2029
Sponsor
- Lead sponsor
- GV20 TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors who are refractory to, intolerant of, or ineligible for standard of care.
Conditions
- Uterine Cervical Neoplasms
- Triple Negative Breast Neoplasms
- Prostatic Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
- Cholangiocarcinoma
- Gallbladder Neoplasms
- Colorectal Neoplasms
- Pancreatic Ductal Adenocarcinoma
- Carcinoma, Non-Small-Cell Lung
- Small Cell Lung Carcinoma
Interventions
GV20-0251Drug
GV20-0251 10/20 mg/kg or SRC-recommended dose in combination with anti-PD-1, Q3W; Part B: RP2D + standard dose anti-PD-1, Q3W.
anti-PD-1 monoclonal antibodiesDrug
anti-PD-1 monoclonal antibodies 200 mg IV Q3W; C1D1 infusion ≥ 60 min, subsequent infusions may be shortened to ≥ 30 min; administered prior to GV20-0251.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting Toxicities (DLTs) and Treatment-Emergent Adverse Events (TEAEs) in Combination with Anti-PD-1 Monoclonal AntibodyTime frame: From Cycle 1 Day 1 dosing (each cycle is 21 days) through 30 days after end of treatment, up to 24 months
- Evaluate the anti-tumor activity of GV20-0251 in combination with anti-PD-1 monoclonal antibodyTime frame: From Cycle 1 Day 1 dosing (each cycle is 21 days) until disease progression or end of study (whichever occurs first, up to 24 months)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.